Phase 2 Brain Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You must have been 26 years old or younger at the time your cancer was diagnosed.
• You must have one of the following confirmed cancer diagnoses: relapsed or treatment-resistant neuroblastoma, relapsed or treatment-resistant embryonal tumor with multilayer rosettes (ETMR), relapsed or treatment-resistant atypical teratoid rhabdoid tumor (ATRT), newly diagnosed diffuse intrinsic pontine glioma (DIPG), relapsed or treatment-resistant Ewing sarcoma, or relapsed or treatment-resistant osteosarcoma.
• Your disease must be assessed and staged within 28 days before starting the study drug.
• For neuroblastoma: your cancer must be high-risk and either came back after standard treatment or did not respond well enough to standard treatment; if you currently have no active disease, you must start the study drug within 60 days of your most recent treatment; if you do have active disease, it must be stable or improving on a recent treatment, and the cancer must not have spread to organs such as the lungs, liver, or brain.
• For ETMR or ATRT: your cancer must have come back or stopped responding to standard treatments including chemotherapy, radiation, and/or high-dose chemotherapy with stem cell rescue; if you have no active disease, you must start the study drug within 60 days of your most recent treatment; if you have active disease, it must be stable or improving on a recent treatment.
• For DIPG: you must have a newly diagnosed typical DIPG (confirmed by scan, no tissue biopsy required) and must start the study drug between 30 and 60 days after finishing standard radiation therapy; your cancer must not have spread beyond the brainstem.
• For Ewing sarcoma or osteosarcoma: your cancer must have come back or stopped responding to standard treatment (chemotherapy plus surgery or radiation); if you have no active disease, you must start the study drug within 60 days of your most recent treatment; if you have active disease, it must be stable or improving on a recent treatment.
• You must be able to swallow capsules.
• If you have cancer affecting your brain or spine and are taking steroids, your steroid dose must have been stable for at least one week, and you must not have worsening fluid buildup in the brain at the time of enrollment.
• You must have recovered from the side effects of any previous cancer treatments, and enough time must have passed since those treatments (the exact waiting period depends on the type of treatment — confirm specific timelines with the trial site).
• You must have a performance score of 60 or higher on a standard activity scale, meaning you are able to carry out at least some daily activities (confirm with trial site).
• Your blood, liver, heart, and kidney function must all be within acceptable ranges as measured by blood tests and scans at the time of enrollment (confirm specific values with trial site).
• If you could become pregnant, you must have a negative pregnancy test before joining and agree to use effective birth control during the trial; if you are breastfeeding, you must agree to stop.
• You (or your legal guardian) must be willing and able to sign an informed consent form.

Who may not be able to join:

• Your body surface area (a measurement related to your height and weight) must not be below a certain minimum size — this is especially relevant for very young or very small children (confirm with trial site).
• You are currently taking part in another clinical trial involving an experimental drug.
• You are currently receiving any other cancer treatment.
• You have an infection that is not well controlled at the time of enrollment.
• In the opinion of the study doctors, you may not be able to safely follow the study's monitoring and safety requirements.

Important: Always verify eligibility with the trial site directly before applying.